|
Liver Cirrhosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
The changes in rat VN due to CCl<sub>4</sub> treatment did not correspond to the changes in plasma levels of human VN caused by LC, the ratio of active molecules, or carbohydrate composition, thereby indicating that CCl<sub>4</sub>-treated rats are not an appropriate model for studying VNs in human LC.
|
30984549 |
2019 |
|
Liver Cirrhosis
|
0.330 |
Biomarker
|
disease |
BEFREE |
Finally, we confirmed that the area under the receiver operating characteristic curve (AUC = 0.944) for the combination of AFP and VTN increased more so than for a single glycopeptide (AUC = 0.889 for AFP and 0.792 for VTN) with respect to discriminating between HCC and cirrhosis serum.
|
31076819 |
2019 |
|
Liver Cirrhosis
|
0.330 |
AlteredExpression
|
disease |
BEFREE |
We find increased core fucosylation of 5 glycopeptides at the stage of liver fibrosis (i.e., N630 of serotransferrin, N107 of alpha-1-antitrypsin, N253 of plasma protease C1 inhibitor, N397 of ceruloplasmin, and N86 of vitronectin), increase of additional 6 glycopeptides at the stage of cirrhosis (i.e., N138 and N762 of ceruloplasmin, N354 of clusterin, N187 of hemopexin, N71 of immunoglobulin J chain, and N127 of lumican), while the degree of core fucosylation of 10 glycopeptides did not change.
|
29427759 |
2018 |
|
Fibrosis, Liver
|
0.320 |
Biomarker
|
disease |
BEFREE |
VN-/- mice showed decreased picrosirius red staining in the liver area and Col1a2 mRNA expression levels, compared with WT mice, indicating that the severity of hepatic fibrosis is attenuated in the CDAHFD-fed VN-/- mice.
|
30887659 |
2019 |
|
Fibrosis, Liver
|
0.320 |
Biomarker
|
disease |
BEFREE |
Interestingly, although we observe an increase in the core fucosylation at N86 of vitronectin in liver fibrosis, core fucosylation decreases on the N169 glycopeptide of the same protein.
|
29427759 |
2018 |
|
Atypical Hemolytic Uremic Syndrome
|
0.310 |
Biomarker
|
disease |
BEFREE |
<i>VTN</i>, which encodes vitronectin, an inhibitor of the terminal complement pathway, is implicated as a novel aHUS-associated gene.
|
30377230 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1.
|
30870427 |
2019 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Occult HBV infection in Chinese blood donors: role of N-glycosylation mutations and amino acid substitutions in S protein transmembrane domains.
|
31516090 |
2019 |
|
Hepatitis B
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
8/13 were OBI, harboring at least one OBI-signature S protein mutation.
|
29263533 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
A nonsense mutant of the hepatitis B virus large S protein antagonizes multiple tumor suppressor pathways through c-Jun activation domain-binding protein1.
|
30870427 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In vivo experiments revealed tumor cells with high and dense cytoplasmic vitronectin expression.
|
31117974 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Human umbilical vein (HUVECs) were cultured in plates coated with fibronectin (FN) or vitronectin (VN) and tested for migration, invasion and proliferation assays in the presence of VEGF, DisBa-01 (1000 nM) or VEGF and DisBa-01 simultaneously.
|
30894182 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, vaccine candidates against MERS-CoV are mainly based upon the viral spike (S) protein, due to its vital role in the viral infectivity, although several studies focused on other viral proteins such as the nucleocapsid (N) protein, envelope (E) protein, and non-structural protein 16 (NSP16) have also been reported.
|
31428074 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recombinant EMC isolates of MERS-CoV, in which the S protein is replaced with those of Amibara isolates, were then generated to test the roles of these proteins in viral properties.
|
31275264 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Preparation of virus-like particle mimetic nanovesicles displaying the S protein of Middle East respiratory syndrome coronavirus using insect cells.
|
31614169 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The receptor-binding domain (RBD) of the S protein contains a critical neutralizing domain and is an important target for development of MERS vaccines and therapeutics.
|
30646569 |
2019 |
|
Middle East Respiratory Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast, changes D510G and I529T increased resistance of S protein-driven entry to neutralization by monoclonal antibodies and sera from MERS patients.
|
30404801 |
2019 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Altogether, specific domains and residues in the HBV S protein that are required for oligomerization and SVP generation were defined.<b>IMPORTANCE</b> The small hepatitis B virus envelope protein S has the intrinsic ability to direct the morphogenesis of spherical 20-nm subviral lipoprotein particles.
|
29540592 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Importantly, the elicited antibodies were able to neutralize HBV infection in an NTCP-expressing infection system (HepG2-NTCP cell line) more efficiently than those induced by mice fed on Lactuca sativa expressing the S protein.
|
30082163 |
2018 |
|
Hepatitis B
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hepatitis B virus (HBV) expresses three co-terminal envelope proteins: large (L), middle (M), and small (S), with the S protein driving the secretion of both virions and subviral particles.
|
29604477 |
2018 |
|
Severe Acute Respiratory Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report on the identification of a putative self-binding β-zipper-forming peptide within the severe acute respiratory syndrome-associated coronavirus spike (S) protein and its application in viral detection.
|
29800727 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Transient knockdown of urokinase/plasminogen activator urokinase receptor (uPAR) in basal-like breast cancer cells grown on vitronectin reduces FRA-1 phosphorylation and stabilization; and uPAR and FRA-1 are required for vitronectin-induced cell invasion.
|
29382358 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
AlteredExpression
|
phenotype |
BEFREE |
HPMCs transfected with miR-99a-5p promoted ovarian cancer invasion and exhibited increased expression levels of fibronectin and vitronectin.
|
30396333 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
BPIFB1 (LPLUNC1) inhibits migration and invasion of nasopharyngeal carcinoma by interacting with VTN and VIM.
|
29123267 |
2018 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Collectively, these results indicate that Vtn acts as a bridge between the SSURE domains of PbsP on the GBS surface and host integrins to promote bacterial invasion of epithelial cells.
|
30030946 |
2018 |